New HIV Drug Offers 6-Month Protection

Zimbabwe is among the first countries to introduce lenacapavir, a groundbreaking HIV prevention drug administered just twice a year. This long-acting injectable offers near-total protection, a significant advancement for individuals at high risk of infection. Constance Mukoloka, a 27-year-old sex worker in Harare, received one of the first doses on Thursday, February 19, 2026, expressing newfound confidence and relief.

Developed by Gilead Sciences, lenacapavir's introduction in Zimbabwe and nine other African nations is supported by PEPFAR and the Global Fund. The drug is provided free to key populations, including adolescent girls, young women, gay men, and pregnant or breastfeeding women. For recipients like Mukoloka, the discreet nature of the injection eliminates the stigma and adherence challenges associated with daily pills.

While health officials hail lenacapavir as a turning point, challenges remain. Funding constraints, infrastructure gaps, and the need for sustained patient engagement are critical hurdles. The cost of mass rollouts is a major concern for many African governments. For instance, Kenya's negotiated price is approximately $54 per person annually, a substantial expense for some.

Despite significant progress in controlling the HIV epidemic in countries like Zimbabwe, new infections persist, especially among young women. Lenacapavir is seen as a vital addition to prevention tools, complementing existing methods like condoms. Its successful implementation hinges on governments navigating economic barriers and strengthening health systems.